Lunar- 2

LUNAR-2 is a pivotal, randomized, open-label trial evaluating the addition of Tumor Treating Fields (TTFields, 150 kHz, delivered by the portable NovoTTF-200T device) to pembrolizumab and platinum-based chemotherapy in patients with metastatic nonÀsmall cell lung cancer (NSCLC) who are treatment-na´ve and ineligible for targeted therapy. It compares this regimen to the standard of careÀpembrolizumab plus platinum-based chemotherapy aloneÀto assess efficacy and safety.;Primary Objectives;Overall Survival (OS): To compare median overall survival between the TTFields + pembrolizumab + chemotherapy arm and the pembrolizumab + chemotherapy arm.;Progression-Free Survival (PFS): To evaluate PFS per RECIST v1.1 criteria, as determined by an independent review committee (BICR), between the two treatment arms.